Not All Antigens Are Created Equally: Progress, Challenges, and Lessons Associated with Developing a Vaccine for Leishmaniasis

Clinical and Vaccine Immunology : CVI
Malcolm S Duthie, Steven G Reed

Abstract

From experimental models and the analyses of patients, it is well documented that antigen-specific T cells are critical for protection againstLeishmaniainfection. Effective vaccines require both targeting to the pathogen and an immune stimulant to induce maturation of appropriate immune responses. While a great number of antigens have been examined as vaccine candidates against variousLeishmaniaspecies, few have advanced to human or canine clinical trials. With emphasis on antigen expression, in this minireview we discuss some of the vaccine platforms that are currently being explored for the development ofLeishmaniavaccines. It is clear that the vaccine platform of choice can have a significant impact upon the level of protection induced by particular antigens, and we provide and highlight some examples for which the vaccine system used has impacted the protective efficacy imparted.

References

Apr 28, 1995·Science·E MougneauN Glaichenhaus
Dec 15, 1993·Proceedings of the National Academy of Sciences of the United States of America·N D ConnellD G Russell
Apr 23, 2003·Vaccine·Eric DumonteilGarcía Miss Maria del Rosario
Jul 24, 2004·Infection and Immunity·Eduardo Fonseca PintoBartira Rossi-Bergmann
Jul 26, 2005·Infection and Immunity·Blaise DondjiDiane McMahon-Pratt
Aug 8, 2006·Biotechnology Journal·Klaus Graumann, Andreas Premstaller
Mar 26, 2009·Microbial Cell Factories·Neus Ferrer-MirallesAntonio Villaverde
Jul 14, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Angamuthu SelvapandiyanHira L Nakhasi
Dec 3, 2010·Applied Microbiology and Biotechnology·Danilo PorroDiethard Mattanovich
Apr 7, 2011·PLoS Neglected Tropical Diseases·UNKNOWN Working Group on Research Priorities for Development of Leishmaniasis VaccinesIsabel Kinney Ferreira de Miranda Santos
Mar 13, 2012·Biotechnology and Bioengineering·Jessica O Josefsberg, Barry Buckland
Jun 16, 2012·Frontiers in Immunology·Vanitha S RamanSteven G Reed
Feb 13, 2013·Vaccine·Jacqueline Araújo FiuzaRicardo Toshio Fujiwara
Jan 1, 2010·Journal of Biomedical Research·Joshua M MutisoMichael M Gicheru
May 16, 2013·Scandinavian Journal of Immunology·S E Degn, S Thiel
Sep 13, 2013·Science Translational Medicine·Rajan GuhaAmitabha Mukhopadhyay
Jun 7, 2015·Transactions of the Royal Society of Tropical Medicine and Hygiene·Christian R Engwerda, Greg Matlashewski
Jul 16, 2015·Clinical & Translational Immunology·Rhea N ColerSteven G Reed
Dec 15, 2015·Parasites & Vectors·Gustavo Domínguez-BernalJavier Carrión
Jan 21, 2016·The American Journal of Tropical Medicine and Hygiene·Ifeoma Okwor, Jude Uzonna
Feb 4, 2016·Human Vaccines & Immunotherapeutics·Elissa M HudspethMaria Elena Bottazzi

❮ Previous
Next ❯

Citations

Mar 29, 2018·Expert Review of Vaccines·Salvador IborraManuel Soto
Jun 20, 2019·Frontiers in Veterinary Science·Javier Moreno
Mar 18, 2020·Antimicrobial Agents and Chemotherapy·Felipe RodriguezRosa A Maldonado
Apr 6, 2021·Frontiers in Cellular and Infection Microbiology·Thalia Pacheco-FernandezHira L Nakhasi
Nov 4, 2021·Expert Review of Vaccines·Paul M KayeStefano Malvolti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Avian Influenza: Innate Immune Adjuvant (ASM)

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.

Avian Influenza: Innate Immune Adjuvant

Adjuvants systems that are added to vaccines against avian influenza have be explored to enhance the innate immune system response against the virus. Here is the latest research on avian influenza and the innate immune adjuvant.